TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7391250
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol (Incentive Loss)
Study: 7391250
Drug: No-dose alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No-dose alcohol
Study: 23647811
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs infusion
Study: 23647811
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs infusion and Control
Study: 14766335
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 to 80 mg/day
Study: 11348605
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 to 40 mg/day
Study: 11255134
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Resistance Training and Walking (RT/W)
Study: 8025759
Drug: ONO-1078 (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-1078 (225 mg)
Study: 2527051
Drug: Acitretin (0.34-0.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (0.34-0.44 mg/kg body weight) + UVB phototherapy (ReUVB)
Study: 979832
Drug: Delta9-tetrahydrocannabinol (THC)
Normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delta9-tetrahydrocannabinol (THC) 10 mg/70 kg
Study: 979832
Drug: Ethanol 0-5
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0-5 g/kg
Study: 979832
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of THC and ethanol
Study: 25296725
Drug: LY2603618 (275
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2603618 (275 mg i.v. infusion) with desipramine (50 mg oral)
Study: 25296725
Drug: Desipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (50 mg oral) alone
Study: 19194313
Drug: Lopinavir/ritonavir film-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir film-coated tablet formulation (LPV/r-fct)
Study: 19194313
Drug: Lopinavir/ritonavir soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir soft gelatine capsules (LPV/r-sgc)
Study: 15386822
Drug: Oralin spray
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oralin spray (100 u)
Study: 15386822
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (0.1 u/kg)
Study: 11293553
Drug: Cefprozil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (30 mg/kg/d in 2 divided doses)
Study: 11293553
Drug: Amoxicillin/clavulanate (45/6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (45/6.4 mg/kg/d plus amoxicillin 45 mg/kg/d in 2 divided doses)
Study: 9555662
Drug: G-699->C polymorphism
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-699->C polymorphism in the putative promoter region
Study: 9555662
Drug: A1098->G polymorphism
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1098->G polymorphism in exon 3
Study: 8035028
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF), 5 micrograms/kg daily for 10 days
Study: 11382894
Drug: GHRH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH treatment
Study: 26239632
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) therapeutic dose (40 mg)
Study: 26239632
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) supratherapeutic dose (160 mg)
Study: 26239632
Drug: Moxifloxacin (MOXI;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (MOXI; 400 mg)
Study: 24041330
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant users (CI)
Study: 19827656
Drug: Anti-platelet treatment
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-platelet treatment
Study: 16160603
Drug: Folic acid,
Normalized name: folic acid, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid, 10 mg/d for 7 days
Study: 11872674
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol (IV PROP, 80 microg/min)
Study: 11872674
Drug: Intravenous phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phentolamine (IV PHEN, 500 microg/min)
Study: 11872674
Drug: Intra-arterial phentolamine
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial phentolamine (IA PHEN, 12 microg/min per 100 ml forearm tissue)
Study: 9539464
Drug: Modified preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified preparation form
Study: 9539464
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation form
Study: 1098132
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glucose and insulin
Study: 1098132
Drug: Glucose infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusions without insulin
Study: 18083781
Drug: COX2 inhibition
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX2 inhibition using 200 mg celecoxib once daily for 14 days
Study: 11197785
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG‐TTS)
Study: 9148337
Drug: Benznidazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole (5 mg/kg/day for 30 days)
Study: 9148337
Drug: Nifurtimox (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifurtimox (5 mg/kg/day for 30 days)
Study: 8241095
Drug: pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40 mg/d
Study: 8241095
Drug: fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fish oil 6 g/d (equivalent to 3 g omega-3 fatty acids/d)
Study: 8241095
Drug: combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined therapy of pravastatin 40 mg/d plus fish oil 6 g/d
Study: 31881614
Drug: 1,4-Diaminobutane (1,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,4-Diaminobutane (1,4 DAB) 0.8% cream applied once per day at night
Study: 31881614
Drug: 1,4-Diaminobutane (1,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,4-Diaminobutane (1,4 DAB) 0.8% cream
Study: 31881614
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (cream base alone)
Study: 26541842
Drug: sitagliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin plus insulin
Study: 26541842
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus insulin
Study: 20510987
Drug: Motor imagery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor imagery integrated into usual therapy
Study: 18688620
Drug: Portal vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal vein infusion of 5-FU 500 mg/m² plus heparin for 24 hours for seven consecutive days plus mitomycin C 10 mg/m² on the first day
Study: 18688620
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 5-FU 500 mg/m² plus heparin for 24 hours for seven consecutive days plus mitomycin C 10 mg/m² on the first day
Study: 14687818
Drug: N-Butyl-2-Cyanoacrylate (cyanoacrylate)
Normalized name: N-(n-Butyl)deoxynojirimycin
DrugBank: Enbucrilate (DB12358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Butyl-2-Cyanoacrylate (cyanoacrylate) glue injection
Study: 7631644
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg cocaine
Study: 1544117
Drug: Lumpectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumpectomy followed by radiation therapy
Study: 3899951
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil 40 mg three times daily
Study: 14618045
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiarrhythmic agents)
Study: 31907186
Drug: Artesunate-Amodiaquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-Amodiaquine (200 mg AS/540 mg AQ) plus Methylene Blue (325 mg)
Study: 22206795
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg under fed conditions
Study: 22206795
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg under fasted conditions
Study: 22206795
Drug: Vandetanib 800
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib 800 mg
Study: 22206795
Drug: Vandetanib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (various doses in Study A)
Study: 22206795
Drug: Vandetanib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (all doses)
Study: 12364632
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg CDP870 (n = 8)
Study: 12364632
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg CDP870 (n = 8)
Study: 12364632
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg CDP870 (n = 8)
Study: 12364632
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment effect of CDP870 (0, 1, 5, 20 mg/kg)
Study: 12364632
Drug: Open-label infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label infusion of 5 or 20 mg/kg CDP870 (n = 32)
Study: 9327688
Drug: Injections before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections before 90 minutes (mean 2.46 ± 1.78; n = 94)
Study: 9327688
Drug: Injections before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections before 90 minutes (mean 2.71 ± 2.42; n = 295)
Study: 9327688
Drug: Injections before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections before 90 minutes (mean 2.53 ± 2.53; n = 184)
Study: 9327688
Drug: Injections before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections before 90 minutes (mean 2.76 ± 2.03; n = 204)
Study: 8452276
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg bolus followed by infusion of 1 micrograms.kg‐1 x min‐1
Study: 8452276
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg/kg bolus followed by infusion of 2 micrograms.kg‐1 x min‐1
Study: 8452276
Drug: Midazolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4 mg/kg bolus followed by infusion of 4 micrograms.kg‐1 x min‐1
Study: 3725003
Drug: Amitriptyline, 50
Normalized name: Perphenazine-Amitriptyline, 50 mg-4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline, 50 mg
Study: 23409601
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training group (1 x 9 reps with 3-kg medicine ball, followed by 3 x 14 reps with water polo ball)
Study: 23409601
Drug: Medicine-ball training
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine-ball training group (3 x 6 reps with 3-kg medicine ball)
Study: 20634482
Drug: Concurrent-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent-adjuvant chemotherapy (CRT) with cisplatin (100 mg/m² every 3 weeks for three cycles) plus radiotherapy
Study: 20634482
Drug: Concurrent-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent-adjuvant chemotherapy (CRT) with cisplatin plus radiotherapy
Study: 20634482
Drug: Concurrent-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent-adjuvant chemotherapy (CRT)
Study: 16473223
Drug: LASIK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LASIK treatment (bilateral, same-day)
Study: 16473223
Drug: Post-LASIK treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-LASIK treatment (surgical emmetropes)
Study: 10502590
Drug: Dehydroepiandrosterone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydroepiandrosterone (50 mg orally each morning for four months)
Study: 10502590
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for four months)
Study: 8595540
Drug: Salmeterol, 50
Normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 50 microgram twice daily
Study: 8595540
Drug: Disodium cromoglycate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate, 20 mg four times daily
Study: 1955633
Drug: Cromolyn (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (20 mg via nebulizer, three times per day)
Study: 1955633
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (inhaled corticosteroid, dosage not specified, three times per day)
Study: 28611102
Drug: Intramuscular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gentamicin and oral amoxicillin for 7 days at health posts
Study: 21878034
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI) prior to Cognitive Behavioural Therapy (CBT)
Study: 15028439
Drug: Prophylactic protocol
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic protocol (40 mg mitomycin-C)
Study: 15028439
Drug: Ablative protocol
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative protocol (80 mg mitomycin-C)
Study: 11842896
Drug: G115 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: G115 400 mg
Study: 11842896
Drug: G115 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: G115 200 mg
Study: 11842896
Drug: G115 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: G115 600 mg
Study: 11842896
Drug: G115 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: G115 200 mg and 400 mg
Study: 9114912
Drug: Dilevalol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 400 mg
Study: 2471287
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (about 840 mg, equivalent to 6 million Kallikrein inactivator units)
Study: 1103273
Drug: Carbenoxolone 100
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone 100 mg three times daily
Study: 1103273
Drug: Geranyl farnesyl
Normalized name: farnesyl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geranyl farnesyl acetate (Gefarnate) 100 mg three times daily
Study: 31192869
Drug: Postoperative anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative anticoagulation (IV heparin or heparin with dextran)
Study: 27434221
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor sitagliptin
Study: 21348806
Drug: liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.2 mg + glimepiride
Study: 21348806
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg + glimepiride
Study: 21348806
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg + glimepiride
Study: 14614218
Drug: Isoflavone extract
Normalized name: flaxseed extract 250 MG / soy isoflavones 250 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone extract (61.8 mg) for three months
Study: 8750523
Drug: Ovarian irradiation
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian irradiation plus prednisone (R + P) 7.5 mg daily for up to five years
Study: 8750523
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (NT)
Study: 8750523
Drug: Ovarian irradiation
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian irradiation with or without prednisone therapy
Study: 1421933
Drug: Oral gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gentamicin (10 mg/kg body weight/day for five days)
Study: 1421933
Drug: Oral gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gentamicin and placebo
Study: 27377549
Drug: Medication Review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Review Tool
Study: 21265353
Drug: Restricted fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted fluid resuscitation (no induction bolus, then LR 2 mL/kg/h)
Study: 21265353
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid resuscitation (500 LR induction bolus, then LR 7 mL/kg/h x 1 h, then 5 mL/kg/h)
Study: 18504252
Drug: Standard radiosensitised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiosensitised induction chemoradiotherapy (arm A) with cisplatin (90 mg/m(2) day 1) plus etoposide
Study: 18504252
Drug: Daily radiosensitised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily radiosensitised induction chemoradiotherapy (arm B) with cisplatin (6 mg/m(2)/day) plus etoposide
Study: 18504252
Drug: Daily radiosensitised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily radiosensitised induction chemoradiotherapy (arm B)
Study: 15687942
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + clavulanic acid
Study: 6365409
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion alone
Study: 6365409
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion with prostaglandin E2
Study: 6365409
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 administration alone
Study: 31671873
Drug: Aromatherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy combined with music therapy
Study: 28602779
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg per day fasted
Study: 28602779
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2)
Study: 25989338
Drug: Briakinumab 200
Normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Briakinumab 200 mg
Study: 25989338
Drug: Briakinumab 400
Normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Briakinumab 400 mg
Study: 25989338
Drug: Briakinumab 700
Normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Briakinumab 700 mg
Study: 10655024
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily
Study: 16047460
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg twice daily
Study: 21417971
Drug: Formaldehyde treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formaldehyde treatment of temporalis muscle fascia grafts
Study: 21417971
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no formaldehyde treatment)
Study: 19113796
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine and sertraline, mirtazapine, and nefazodone as pharmacologic therapy for depression in heart failure patients.
Study: 19113796
Drug: Beta-blockers in
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers in patients with depression and heart failure.
Study: 11574184
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg alone for 30 days
Study: 11574184
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + continuous combined medroxyprogesterone acetate (MPA) 2.5 mg/daily for 28 days
Study: 11574184
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + cyclical MPA (10 mg o.d. from day 16 to day 28)
Study: 9625845
Drug: Paclitaxel (TX)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (TX) 175 mg/m2 by 3 h i.v. infusion every 21 days
Study: 8160217
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy and carotid endarterectomy
Study: 3116132
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) for 9.7 +/- 1.1 days
Study: 26599376
Drug: Aspirin intake
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin intake at 8.00 AM